MS

Manju Singla

Active Director Director DIN 02634657
DIN 02634657 First appointment Apr 2009 Primary industry Trading
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Apr 2009
Shareholding value •••• Premium profile

About Manju Singla

Data last updated:

Manju Singla is a Director at La Pharmachem Private Limited (since 2009). The company operates in Trading. La Pharmachem Private Limited reported revenue of ₹4.34 Cr (FY 2025).

DIN 02634657
Primary Designation Director
Industry Trading
First Appointment 30 Apr 2009
Oldest Company Age 48 yrs
Largest company La Pharmachem Private Limited · ₹4.34 Cr (FY 2025)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
La Pharmachem Private Limited U24231PB1977PTC003788
Director30 Apr 20091977₹4.34 Cr (FY 2025)Active

Board colleagues of Manju Singla

Directorship timeline

Open interactive timeline →
La Pharmachem Private Limited
Premium access

Shareholding and investment profile for Manju Singla

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Manju Singla

Manju Singla currently holds 1 directorship: La Pharmachem Private Limited (Director, since 30 Apr 2009, revenue ₹4.34 Cr (FY 2025)).

Manju Singla was first appointed on 30 Apr 2009 as Director at La Pharmachem Private Limited.

The current boards of Manju Singla's companies include Abhishek Singla (La Pharmachem Private Limited), Pardeep Kumar Singla (La Pharmachem Private Limited), Yatish Singla (La Pharmachem Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available